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Abstract The carboxy-terminal region of utrophin, like the
homologous proteins dystrophin, Drp2 and dystrobrevins, con-
tains structural domains frequently involved in protein^protein
interaction. These domains (WW, EF hands, ZZ and H1^H2)
mediate recognition and binding to a multicomponent complex of
proteins, also known as dystrophin-associated proteins (DAPs)
for their association with dystrophin, the product of the gene,
mutated in Duchenne muscular dystrophy. We have exploited
phage display and in vitro binding assays to study the recognition
specificity of the different domains of the utrophin carboxy-
terminus. We found that none of the carboxy-terminal domains
of utrophin, when isolated from its structural context, selects
specific ligand peptides from a phage-displayed peptide library.
By contrast, panning with an extended region containing the
WW, EF hands, and ZZ domain defines the consensus binding
motif, PPxY which is also found in L-dystroglycan, a component
of the DAP complex that interacts with utrophin in several
tissues. WW-mediated binding to PPxY peptides and to L-
dystroglycan requires the presence of the EF hands and ZZ
domain. When the ZZ domain is either deleted or engaged in
binding to calmodulin, the utrophin L-dystroglycan complex
cannot be formed. These findings suggest a potential regulatory
mechanism by means of which the attachment of utrophin to the
DAP complex can be modulated by the Ca2-dependent binding
of calmodulin. The remaining two motifs found in the carboxy-
terminus (H1^H2) mediate the formation of utrophin^dystro-
brevin hybrids but do not select ligands in a repertoire of random
nonapeptides.
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1. Introduction
Utrophin is a ubiquitous protein that is homologous to
dystrophin, the protein associated with Duchenne muscular
dystrophy (DMD) [1]. It has been proposed that utrophin
and dystrophin have a role in connecting cytoskeletal actin
to a multicomponent protein complex known as dystrophin-
associated protein (DAP) complex, which is localized at the
cell membrane and interacts with the extracellular matrix
[1,2]. The carboxy-terminal region of dystrophin mediates the
connection with the DAP complex through a series of modu-
lar binding domains: a WW domain [3], a region containing
EF hands motifs [4], a cysteine-rich domain, containing a
putative zinc ¢nger (ZZ) [5] and two regions, H1 and H2,
that are predicted to fold into a coiled-coil structure [6]. The
modular organization of the carboxy-terminal region and its
amino acid sequence are well conserved in utrophin. The pro-
tein targets of some of the dystrophin carboxy-terminal do-
mains are already known: the WW domain along with the
adjacent EF hands bind to the cytoplasmic tail of L-dystro-
glycan, a transmembrane component of the DAP complex
that interacts with K-dystroglycan on the outer face of the
membrane [7^10]. The ZZ domain binds to calmodulin, the
major regulator of calcium-dependent kinases [11], while the
H1^H2 coiled-coil region is responsible for heterodimerization
with the corresponding helices of dystrobrevin [12].
Utrophin is found associated with a di¡erent subtype of the
DAP complex, including some of the DAPs and synapse-as-
sociated proteins such as rapsyn and agrin [13]. The distinct
tissue distribution and cell localization suggest that dystrophin
and utrophin, although similar, may play di¡erent roles and
possibly display a di¡erent protein binding speci¢city. Never-
theless, the ¢nding that utrophin can replace dystrophin at the
sarcolemma of developing and regenerating muscles [14,15] or
in dystrophin-de¢cient mdx mice [16] has emphasized the par-
tially overlapping function of the two proteins and has in-
creased the interest in possible therapeutic use of utrophin
for DMD [16,17].
To address these points, we have analyzed the binding po-
tential of the di¡erent domains of the carboxy-terminus of
utrophin using peptide repertoires displayed on phages and
in vitro binding assays with L-dystroglycan, calmodulin and
dystrobrevin.
2. Materials and methods
2.1. Constructs
We have used the tools provided by the SMART program to iden-
tify the structural domains (and their boundaries) in the carboxy-
terminus of utrophin [18]. Di¡erent fragments of human utrophin
cDNA were ampli¢ed by the polymerase chain reaction (PCR) from
a fetal brain cDNA library (kindly provided by TIGEM), using spe-
ci¢c oligonucleotides, inserting BamHI and EcoRI restriction sites.
Whenever possible, we took advantage of published expression data
of equivalent domains. For the WW domain, for instance, Macias et
al. [19] have shown that the minimal WW domain of YAP65, as
determined by multiple alignment, cannot fold properly unless it is
extended by a heptapeptide at the amino-terminus and a decapeptide
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at the carboxy-terminus. Utrophin fusion constructs that contain iso-
lated domains include: 10 and 15 residues at the N- and C-termini of
the WW domain; 20 and 15 residues at the N- and C-termini of the
ZZ domain; 60 and 8 residues at the N- and C-termini of the H1^H2
domain.
Ampli¢ed fragments were cloned into BamHI and EcoRI sites of
pGEX2TK vector (Amersham Pharmacia Biotech). cDNA fragments
corresponding to the H1^H2 region of dystrophin (aa 3464^3605),
DRP2 (aa 745^880) and dystrobrevin (aa 372^505) were subcloned
into SalI^BamHI sites of pYEX vector, a derivative of pGEX2TK
with a di¡erent polylinker. Construct pGEX2TK-DGL, producing
the cytoplasmic moiety of human L-dystroglycan fused to glutathione
S-transferase (GST; aa 774^895), was kindly provided by X. Espanel.
Construct His-DGL, directing the synthesis of the corresponding re-
gion as a histidine-tagged protein, was obtained by PCR ampli¢cation
and subcloning of the same L-dystroglycan fragment into SacI/SalI
sites of the pQE30 vector (Qiagen). All the constructs were trans-
formed into the protease-defective strain BL21 (DE3). Constructs in-
cluding either WW, EF hands or ZZ domains were very susceptible to
endogenous proteases especially in the linker following the GST pro-
tein. This protease susceptibility was already described for the corre-
sponding dystrophin fusion constructs [7,8,20,21]. GST fusion pro-
teins were induced with 1 mM isopropyl-1-thio-L-D-galactopyrano-
side (IPTG, Sigma-Aldrich) for only 2 h at 37‡C to reduce protein
degradation. After cell sonication, a protease inhibitor cocktail
(Boehringer Mannheim) was added and the lysates cleared by centri-
fugation. Supernatants were incubated with glutathione-Sepharose 4B
beads (Amersham Pharmacia Biotech) following the supplier’s proto-
cols.
2.2. Phage display methodology
Library construction and selections were performed as previously
described [22]. In the micropanning assay, phages were subjected to a
panning cycle: 106 transducing particles of each clone were incubated
with 5 Wg of GST fusion proteins bound to glutathione-agarose for 1 h
at 4‡C, in PBS, 0.5% Tween 20. After extensive washing, the bound
phages were eluted and titered.
2.3. In vitro a⁄nity binding assays
Puri¢ed GST^DGL was in vitro labelled with [Q-32P]ATP using
bovine heart protein kinase catalytic subunit (P2645, Sigma-Aldrich)
and subsequently treated with thrombin protease to release the GST
portion (Sigma-Aldrich), according to the manufacturer’s instructions.
Inspection of the dystroglycan sequence included in our constructs did
not reveal residues that are likely to be fully phosphorylated by this
kinase [23]. Approximately 10 Wg of GST fusion proteins, bound to
agarose, were incubated with 32P-DGL (1 Wg/ml) in 100 mM NaCl,
160 mM NaH2PO4, 350 mM Na2HPO4 (PBS), 500 WM phenylmeth-
ylsulfonyl £uoride, for 12 h at 4‡C. After 5 washes with PBS, samples
were analyzed by 5^10% SDS^PAGE and radioactivity estimated us-
ing a phosphor-imager (STORM, Molecular Dynamics).
Binding to calmodulin agarose (Sigma-Aldrich) was assayed by in-
cubation of 1 ml of TTBS bacterial extracts (50 mM Tris^HCl pH 7.5,
150 mM NaCl, 1% Triton X-100), expressing GST^ZZ and GST
proteins, with 10 Wl of resin suspension (approximately 10 Wg of cal-
modulin), in the presence of 0.2 mM CaCl2 or 50 mM EGTA, for 1 h
at 4‡C. Proteins retained by the resin were analyzed by SDS^PAGE
stained with Coomassie brilliant blue. Competition analysis of L-dys-
troglycan and calmodulin binding was performed by incubating 1 ml
of bacterial extracts containing GST^WWEFZZ, His^DGL or both,
with either calmodulin-agarose or glutathione-agarose, for 1 h at 4‡C,
in the presence of 0.2 mM CaCl2. Samples were separated on 5^10%
SDS^PAGE and Western blotting was performed as previously de-
scribed [7].
2.4. Ligand dot overlay assay
Puri¢ed GST^H1H2 fusion proteins (1 and 5 Wg) were immobilized
onto nitrocellulose (Schleicher and Schuell). After 30 min incubation
with blocking solution (PBS, 3% bovine serum albumin, 0.05%
Tween 20) ¢lters were incubated with 32P-labelled GST^H1H2^Utr,
and GST^H1H2^Dybr (500 ng/ml) in PBS, for 12 h at 4‡C. After
two washes with PBS, ¢lters were dried and exposed overnight to a
radiographic ¢lm. The same ¢lters were probed with an antibody
against GST to monitor the amount of proteins loaded (data not
shown).
3. Results
3.1. Construction of plasmids encoding utrophin GST fusion
proteins
In order to study the peptide binding speci¢city of the
structural domains at the carboxy-terminus of utrophin, we
engineered a collection of plasmids directing the synthesis of
di¡erent utrophin fragments as carboxy-terminal fusions to
GST (Fig. 1a). Domain borders were determined on the basis
of sequence alignment using the SMART program [18] and
published data about surrounding sequences, necessary for
proper folding of domains [5,6,19].
In agreement with expression experiments of fusion proteins
containing di¡erent C-terminal fragments of dystrophin
[7,8,20,21] we observed more than one GST fusion protein
in each expression experiment indicating degradation during
expression/puri¢cation (Fig. 2). However, at least 50% of the
product migrates consistently with the predicted MW of the
full-length product and the most protease-susceptible site is
the peptide linker following the GST protein. The presence
of su⁄cient amounts of soluble intact fusion proteins to per-
form binding analysis was evaluated by immunoblotting with
anti-GST (Figs. 3b and 4a).
3.2. Phage display analysis
The puri¢ed fusion proteins, bound to glutathione-agarose
beads, were used to screen multivalent phage peptide libraries,
as previously described [22^24]. None of the utrophin con-
structs containing only isolated domains selected speci¢c pep-
tides from the phage display library. This is particularly sur-
prising for the WW domain since all the WW domains
identi¢ed and tested up to now, with the exception of dystro-
phin [7], are functionally independent and able to speci¢cally
bind to proline-rich peptide ligands even when isolated from
their protein [25^28]. Macias et al. [19] have observed that the
Table 1
Peptides selected by WW-EF-ZZ fusion protein
Sequence alignment of phage-displayed peptides and derived consen-
sus sequence.
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minimal WW domain sequence, as de¢ned by multiple se-
quence alignment, must be extended at both the amino- and
carboxy-side in order to obtain proper folding of the YAP 65-
WW domain. We took advantage of this observation in the
design of the utrophin WW and ZZ fusion constructs. Not-
withstanding this, neither isolated domain selects speci¢c li-
gands from the nonapeptide repertoire. In contrast, a larger
construct (WW-EF-ZZ), which includes the region from aa
2803 to 3125, containing the WW, EF-hands and ZZ do-
mains, selected a family of peptides, which de¢ne the consen-
sus motif PPxY (Table 1). At position 3 indicated with an x
(any residue), we observe a preference for proline or alanine.
Some of the selected peptides also display an arginine at po-
sitions 31 or 32 preceding the PPxY motif. Indeed, the se-
quence RSPPPY represents one of the two PPxY motifs lo-
cated at the carboxy-terminal end of the cytoplasmic region of
L-dystroglycan. The motif PPxY has already been identi¢ed as
the preferred ligand for group I WW domains [3,27]. Re-
cently, it has been shown that also the dystrophin WW do-
main requires adjacent regions to bind to the target, L-dystro-
glycan, through the same RSPPPY core sequence [7].
We found that deletions of either the WW domain (vW,
vWW) or the ZZ domain (vZZ) abolishes phage binding (Fig.
1b). To analyze the direct involvement of these domains in the
binding to the PPxY motif we changed, by site-directed muta-
genesis, speci¢c residues in crucial positions of either the WW
or the ZZ domain. To a¡ect the WW binding cleft, we
changed the second conserved tryptophan residue of the
WW domain (W2840) into phenylalanine. It has already
been shown that WW domains of di¡erent proteins when
mutated in this residue lose their ability to bind the PPxY
peptide targets [19,25,26]. The structure of the ZZ domain is
not known and it is therefore impossible to rationally plan a
mutation that a¡ects its function(s). We chose to substitute
the fourth conserved cysteine residue of the ZZ domain
(C3097) with tyrosine because this residue is predicted to par-
ticipate in the formation of the putative zinc ¢nger(s). Fur-
thermore, its functional importance has been suggested by the
identi¢cation of a substitution in a corresponding position
(C3340Y) in the dystrophin gene of a DMD patient [29].
Single point mutants were generated in the construct WW-
EF-ZZ and tested by micropanning on phages displaying the
IRSPPPYEP peptide. We chose this peptide, because it con-
tains six (in bold) out of nine residues identical to the car-
boxy-terminal sequence of L-dystroglycan. Our results show
that phages carrying IRSPPPYEP peptides were e⁄ciently
Fig. 1. a: Schematic diagram of the domain organization of utrophin carboxy-terminal region. Names of the GST fusion proteins containing
the corresponding utrophin peptides are on the left, amino acids at the extremities of each fragment are indicated on the right. b: Enrichment
of phages displaying speci¢c peptide ligands after three panning cycles with the GST fusion proteins linked to glutathione-agarose.
Fig. 2. 32P-labelled L-dystroglycan was incubated with GST fusion proteins: WWEFZZ (1 and 8); vW (2); vWW (3); vZZ (4); ZZ (5); WW
(6); mut W-F (9); mut C-Y (10) and GST (7 and 11) as negative control. Retention was detected by SDS-PAGE and Coomassie brilliant blue
staining (panels a and c) and autoradiography (panels b and d). Molecular weight markers are indicated on the left while relative positions of
the GST-fused proteins and of the L-dystroglycan fragment (DGL) are indicated on the right. An extra band of bacterial origin, which does
not stain with anti-GST antibodies (data not shown), copuri¢es with the vW fusion protein (lane 2).
FEBS 23537 7-4-00
A. Tommasi di Vignano et al./FEBS Letters 471 (2000) 229^234 231
retained by the ZZ mutant protein but not by the mutant
a¡ecting the WW domain. M13 wild-type phage was used
as negative control (Table 2).
3.3. Binding to the cytoplasmic region of L-dystroglycan
Next, we asked whether the observed requirement for WW
and ZZ modules for binding to PPxY peptides could be mir-
rored by an analogous behavior in binding to the entire cy-
toplasmic region of L-dystroglycan. We have analyzed this
interaction in vitro, using the puri¢ed cytoplasmic region of
human L-dystroglycan labelled with 32P. The amount of la-
belled L-dystroglycan retained by the utrophin fragments,
bound to glutathione agarose, was analyzed by SDS^PAGE
and autoradiography. The results shown in Fig. 2 are in
agreement with the phage display data. Neither WW nor
ZZ binds, as an isolated domain, to L-dystroglycan. The larg-
est construct (WW-EF-ZZ) binds e⁄ciently, while deletions of
the WW domain or of the ZZ domain completely abolish the
binding. This is in contrast to data shown for analogous dys-
trophin constructs, missing the ZZ domain (WW-CRvZZ),
that displayed a residual binding to L-dystroglycan [7].
Moreover, the W-F substitution in the WW domain signi¢-
cantly a¡ects the interaction, while the C-Y mutation in the
ZZ domain does not. These results indicate that, as in the
homologous protein dystrophin, alteration of the WW do-
main of utrophin impairs the interaction with the PPPY pep-
tide, present in the L-dystroglycan cytoplasmic tail.
3.4. Binding to calmodulin
Two low-a⁄nity calmodulin binding sites have been identi-
¢ed in the amino-terminal regions of utrophin and dystrophin
[30,31]. A third site, with higher a⁄nity, has been described at
the carboxy-terminus of mouse dystrophin, in the cysteine-
rich region between residues 3293 and 3349 [11]. By analogy,
the corresponding region of utrophin has been suggested to
have the same binding potential [32]. We have tested this
interaction in vitro, by binding to calmodulin-agarose. Utro-
phin GST^ZZ (aa 3045^3125) speci¢cally binds to calmodulin
in a calcium-dependent manner while recombinant GST is not
retained (Fig. 3). Thus the ZZ region of utrophin is necessary
for binding both to calmodulin and to L-dystroglycan. Next
we asked whether the GST^WWEFZZ protein could bind L-
dystroglycan and calmodulin simultaneously. The results of
the experiment illustrated in Fig. 4 demonstrate that the two
ligands are mutually exclusive and that either calmodulin can-
not bind to utrophin when already engaged with dystroglycan,
or its binding displaces dystroglycan.
3.5. Binding to the H1^H2 region of dystrobrevin
The H1^H2 region is predicted to fold into two tandem K-
helical polypeptides and to mediate protein dimerization via
formation of coiled-coils [6]. It has been reported that the
Fig. 3. Binding of utrophin ZZ domain to calmodulin. Bacterial extracts (E) containing GST^ZZ or GST proteins were incubated with CaM-
agarose in the presence of EGTA or calcium. Proteins retained on the resin were analyzed by SDS^PAGE stained with Coomassie brilliant
blue (a). The arrow points to a high MW band corresponding to a bacterial protein that binds to calmodulin. A gel similar to the one in (a)
was transferred to a membrane and probed with an anti-GST antibody (b).
Fig. 4. Competition of utrophin/L-dystroglycan binding by calmodu-
lin. Bacterial extracts containing the cytoplasmic region of L-dystro-
glycan fused to a poly-histidine tail (1) and the GST^WWEFZZ
utrophin fusion protein (2) were mixed (3) and the utrophin fusion
protein was puri¢ed by a⁄nity either to calmodulin (CaM) agarose
or to glutathione (GSH) agarose. Retained proteins were revealed
with anti-GST (a) and anti-DGL (b) respectively.
Table 2
Micropanning analysis of phages displaying a dystroglycan-like pep-
tide
Target protein Phage IRSPPPYEP Phage M13
GST 105 105
GST^WWEFZZ 10 105
GST^WWWÿFEFZZ 5U102 105
GST^WWEFZZCÿY 10 105
Numbers indicate the phage input/output rate after a panning cycle.
M13 wild-type phage is the negative control.
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utrophin H1^H2 region, from aa 2753 to 3432, can mediate
the formation of heterodimers with K-dystrobrevin-1 in the
yeast two-hybrid assay and in a binding assay between in vitro
translated proteins [33]. We have con¢rmed these results by a
dot overlay assay (Fig. 5) and we have mapped more precisely
the region essential for binding to a short fragment of 141
amino acids (3221^3361).
Utrophin does not heterodimerize with dystrophin or
DRP2 H1^H2 domains, while a speci¢c interaction with K-
dystrobrevin is con¢rmed by this technique. The reciprocal
experiment, using dystrobrevin as a probe, demonstrates
that not only dystrophin and utrophin but also the related
protein DRP2 can bind to dystrobrevin.
4. Discussion
The dystroglycan complex, formed by K- and L-dystrogly-
cans, spans the membrane and connects the extracellular ma-
trix to the cytoskeleton. This bridging function is mediated by
dystrophin at the sarcolemma and by utrophin at neuromus-
cular junctions [33,34]. Our analysis revealed that the interac-
tion between utrophin and L-dystroglycan mirrors that of the
homologous protein dystrophin and it is mainly mediated by
the utrophin WW domain recognizing the PPPY peptide at
the carboxy-terminus of the L-dystroglycan. Saito et al. [10]
have proposed that a L-dystroglycan peptide of 26 amino
acids, located in the membrane-proximal region, increases
the binding a⁄nity of the cytoplasmic tail for dystrophin.
Rentschler et al. [7] have found that the EF hand-like regions,
following the WW domain sequence in the C-terminal region
of dystrophin, are necessary for WW binding.
In this report we have shown that the integrity of the utro-
phin WW-EF-ZZ region is essential for e⁄cient binding to L-
dystroglycan and to small peptides selected from a peptide
phage library.
Deletion of the ZZ domain from the utrophin construct
completely abolishes the binding; the same deletion in an
analogous construct of dystrophin only slightly reduces the
binding to L-dystroglycan [7]. This discrepancy could be due
to the di¡erent assay or to speci¢c di¡erences present in the
sequences of the two proteins.
Although all the members of the dystrophin family have
apparently similar domains, several residues within these do-
mains di¡er signi¢cantly. These amino acids could represent
the main determinants of binding speci¢city for modular pro-
tein domains [28].
Several isoforms of dystrophin and utrophin have been
identi¢ed. Although they are relatively abundant gene prod-
ucts in some tissues, their respective roles are still unclear.
Dp71 is a short isoform of dystrophin, containing only the
carboxy-terminal region of the protein; a corresponding tran-
script for the homologous utrophin isoform, Up71, has re-
cently been described in several human and mouse tissues
[35]. We have designed the oligonucleotides to generate the
constructs vWW and vW to produce proteins, respectively
starting from the proposed translation initiation site of
Up71 (aa 2845) and from the point where Up71 and Dp71
diverge (aa 2833). vWW completely misses the WW domain,
while vW retains only half of it. Both proteins were found to
be unable to bind to L-dystroglycan (Fig. 2).
The role of the ZZ domain is still unclear. We have shown
that this region of utrophin mediates binding to calmodulin,
as already described for dystrophin. However the functional
relevance of this interaction is not established. More impor-
tantly we have shown that the ZZ domain is required for
binding to L-dystroglycan. A direct participation of this do-
main in the binding to the short PPxY peptides, selected from
Fig. 5. Dot overlay assay. Fusion proteins containing H1^H2 re-
gions of dystrophin (Dys), utrophin (Utr), dystrophin-related pro-
tein 2 (DRP2) and dystrobrevin (Dyb), immobilized on nitrocellu-
lose ¢lters, were tested for binding to 32P-labelled Utr (upper panel)
and Dyb (lower panel).
Fig. 6. Schematic representation of regulation of the DAP complex by calmodulin association. The cartoon represents the predicted e¡ects of
raising the calcium concentration upon formation of a complex between cytoskeleton, utrophin and the dystroglycan in the presence of calmod-
ulin.
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the larger construct WW-EF-ZZ, is unlikely. Computer-aided
modeling of the WW domain of dystrophin and utrophin,
using the experimentally determined three-dimensional struc-
ture of the WW domain of YAP [19] as a sca¡old, indicates
that the PPPY peptide can adapt to the WW binding cleft
without any need to postulate direct contacts with the ZZ
domain. Thus we favor an interpretation that advocates a
stabilizing or modifying e¡ect of the ZZ domain on the
WW structure rather than the formation of direct contacts
with the proline-rich target peptide. The important role of
the ZZ domain in dystroglycan binding is consistent with
our ¢nding that utrophin binding is prevented when the ZZ
domain is engaged with calmodulin.
It has been shown that calmodulin inhibits the binding of
amino-terminal regions of utrophin (or dystrophin) to F-ac-
tin, suggesting calmodulin modulation of the attachment to
the cytoskeleton [31]. Moreover, inhibition of in vitro inter-
action between dystrophin and syntrophin fusion proteins by
calmodulin was also reported [32]; in contrast competitive
binding of dystroglycan and calmodulin to dystrophin has
not been previously tested. The work presented here provides
evidence of a further mechanism by means of which also the
binding to dystroglycan could be regulated by calmodulin.
Taken together all these observations support the model illus-
trated in Fig. 6 where association of utrophin (and dystro-
phin) to the DAP complex and cytoskeleton could be modu-
lated by variations in calcium concentration. Whether this
mechanism has any functional relevance in vivo remains to
be established.
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